ProfileGDS5678 / 1431117_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 63% 63% 63% 62% 63% 65% 63% 62% 62% 63% 63% 64% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9353365
GSM967853U87-EV human glioblastoma xenograft - Control 23.7625763
GSM967854U87-EV human glioblastoma xenograft - Control 33.7552963
GSM967855U87-EV human glioblastoma xenograft - Control 43.7219563
GSM967856U87-EV human glioblastoma xenograft - Control 53.6863962
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8575463
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0002965
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7731863
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7134362
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7148762
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7884663
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.716563
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8522964
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7891563